PRCT241220P110000
- 18.70
- 0.000.00%
PROCEPT BioRobotics Newsroom
Wells Fargo Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Raises Target Price to $112
Procept BioRobotics Resumed With an Overweight at Wells Fargo
Procept Biorobotics Insider Sold Shares Worth $2,584,638, According to a Recent SEC Filing
Insider Sale: President of $PRCT (PRCT) Sells 18,144 Shares
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
PROCEPT BioRobotics Analyst Ratings
Morgan Stanley Initiates PROCEPT BioRobotics at Overweight
Morgan Stanley Initiates PROCEPT BioRobotics(PRCT.US) With Buy Rating, Announces Target Price $105
PROCEPT BioRobotics: Strong Market Positioning and Growth Potential With Aquablation Technology and Hydros System
Leerink Partners Sticks to Their Buy Rating for PROCEPT BioRobotics (PRCT)
PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024
Express News | Procept Biorobotics Corp : Leerink Partners Cuts Target Price to $102 From $103
Alkermes, DaVita, Jabil, Ralph Lauren, Among Potential M&A Candidates - BofA
PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 29% Jump Shows Its Popularity With Investors
Sector Update: Health Care Stocks Weaker Late Afternoon
PROCEPT Started With Hold at Jefferies on Valuation
Looking Into PROCEPT BioRobotics's Recent Short Interest
The Analyst Landscape: 6 Takes On PROCEPT BioRobotics